Journal article · 2019 · Open access
Understanding key symptoms, side effects, and impacts of HR+/HER2- advanced breast cancer: qualitative study findings
Journal of Patient-Reported Outcomes, 3(1), 10 · Published 7 February 2019 · DOI 10.1186/s41687-019-0098-1
In brief
“Understanding key symptoms, side effects, and impacts of HR+/HER2- advanced breast cancer: qualitative study findings” is a 2019 journal article by Nina Galipeau and 5 co-authors, published in Journal of Patient-Reported Outcomes. OpenAlex counts 28 citations as of 22 November 2026. It is open access under a CC BY licence: the full text is free to read at Journal of Patient-Reported Outcomes.
- Citations
- 28
- Most cited in
- 2020 (8)
- Field-weighted impact
- 1.54
- References
- 21
- Authors
- 6
Abstract
BACKGROUND: Patients with breast cancer experience a variety of disease symptoms and treatment-related side effects that can adversely affect functioning. The breast cancer experience may differ across disease stages and biomarker subtypes. This study identified relevant disease symptoms, treatment-related side effects, and physical functioning impacts in women with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer. METHODS: One-on-one concept elicitation interviews were conducted with 15 patients with HR+/HER2- advanced breast cancer. Open-ended questions about patient experience with breast cancer and its treatment were drawn from a semi-structured interview guide. All interviews were audio-recorded and transcribed verbatim, and codes were used to document and organize patient descriptions of their experiences. Coded concepts were defined, supported by exemplary patient quotes, and analyzed for frequency of mention and saturation. Five interviews with experienced oncologists were conducted to supplement the concept elicitation interviews. RESULTS: The average age of the patients was 66 years. Most (53%) self-identified as White/Caucasian; 40%, as Black/African American. Patients were reported to have metastases to bone (87%), liver (20%), lung (13%), skin (7%), and lymph nodes (7%). The most frequently reported disease-related concepts were fatigue and lump in breast (47% each) and pain (40%), while the most frequently reported treatment-related side effects were hair loss (67%), fatigue/tiredness (47%), and nausea (40%). Patients identified 10 concepts associated with both breast cancer and its treatment, including fatigue/tiredness, shortness of breath, weakness, and nausea. The most frequently reported impacts on physical function included working around home (73%), walking (73%), and cooking (53%). The most frequently reported symptoms and side effects from the expert perspective included fatigue, pain, and hot flashes (n = 5 each, 100%), while the ability to work (n = 5, 100%) and walk (n = 3, 60%) were reported impacts, aligning with those concepts reported by patients. The resulting concepts were organized into a patient-based conceptual model. CONCLUSIONS: Patients have varied experiences due to HR+/HER2- advanced breast cancer and its treatment, and commonly experience fatigue/tiredness, hair loss, general pain, lump in breast, and nausea, as well as impacts to physical functioning (specifically, activities of daily living and mobility).
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Galipeau, N., Klooster, B., Krohe, M., Tang, D. H., Revicki, D. A., & Cella, D. F. (2019). Understanding key symptoms, side effects, and impacts of HR+/HER2- advanced breast cancer: qualitative study findings. Journal of Patient-Reported Outcomes, 3(1), 10. https://doi.org/10.1186/s41687-019-0098-1
MLA 9
Galipeau, Nina, et al. “Understanding key symptoms, side effects, and impacts of HR+/HER2- advanced breast cancer: qualitative study findings.” Journal of Patient-Reported Outcomes, vol. 3, no. 1, 2019, p. 10. https://doi.org/10.1186/s41687-019-0098-1.
Chicago
Galipeau, Nina, Brittany Klooster, Meaghan Krohe, Derek H. Tang, Dennis A. Revicki, and David F Cella. 2019. “Understanding key symptoms, side effects, and impacts of HR+/HER2- advanced breast cancer: qualitative study findings.” Journal of Patient-Reported Outcomes 3 (1): 10. https://doi.org/10.1186/s41687-019-0098-1.
Harvard
Galipeau, N. et al. (2019) ‘Understanding key symptoms, side effects, and impacts of HR+/HER2- advanced breast cancer: qualitative study findings’, Journal of Patient-Reported Outcomes, 3(1), p. 10. doi:10.1186/s41687-019-0098-1.
IEEE
N. Galipeau, B. Klooster, M. Krohe, D. H. Tang, D. A. Revicki, and D. F. Cella, “Understanding key symptoms, side effects, and impacts of HR+/HER2- advanced breast cancer: qualitative study findings,” Journal of Patient-Reported Outcomes, vol. 3, no. 1, p. 10, 2019, doi: 10.1186/s41687-019-0098-1.
BibTeX
@article{galipeau2019understanding,
title = {{Understanding key symptoms, side effects, and impacts of HR+/HER2- advanced breast cancer: qualitative study findings}},
author = {Galipeau, Nina and Klooster, Brittany and Krohe, Meaghan and Tang, Derek H. and Revicki, Dennis A. and Cella, David F},
journal = {Journal of Patient-Reported Outcomes},
year = {2019},
volume = {3},
number = {1},
pages = {10},
doi = {10.1186/s41687-019-0098-1},
url = {https://doi.org/10.1186/s41687-019-0098-1}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2019 | 1 | |
| 2020 | 8 | |
| 2021 | 4 | |
| 2022 | 2 | |
| 2023 | 3 | |
| 2024 | 3 | |
| 2025 | 3 | |
| 2026 | 4 |
Its field-weighted citation impact is 1.54: it has been cited 1.54 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Health Sciences › Medicine › Oncology › Cancer survivorship and care
- HR+/HER2- advanced breast cancer
- patient experience
- disease symptoms
- treatment side effects
- physical function
- fatigue
- hair loss
- nausea
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Galipeau, N., Klooster, B., Krohe, M., Tang, D. H., Revicki, D. A., & Cella, D. F. (2019). Understanding key symptoms, side effects, and impacts of HR+/HER2- advanced breast cancer: qualitative study findings. Journal of Patient-Reported Outcomes, 3(1), 10. https://doi.org/10.1186/s41687-019-0098-1
How many times has this paper been cited?
28 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Journal of Patient-Reported Outcomes: sign in and open the PDF from this page.
Who wrote this paper?
Nina Galipeau, Brittany Klooster, Meaghan Krohe, Derek H. Tang, Dennis A. Revicki, David F Cella.
What is the DOI of this paper?
10.1186/s41687-019-0098-1, permanently at https://doi.org/10.1186/s41687-019-0098-1. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.